Michael Douglas

Title(s)Program Manager, Clinical Pharmacy
SchoolSchool of Pharmacy
Address490 Illinois Street, #3228
San Francisco CA 94158
Phone415-502-4025
Emailmichael.douglas@ucsf.edu
ORCID ORCID Icon0000-0001-8517-6678 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    SUNY-College of Environmental Science and Forestry, Syracuse, NYMS05/1997Molecular Biology
    SUNY-College of Environmental Science and Forestry, Syracuse, NYBS05/1995Plant Biotechnology

    Collapse Overview 
    Collapse Overview
    I serve as the program manager in the UCSF Department of Clinical Pharmacy in the laboratory of Akinyemi Oni-Orisan, PharmD, PhD. As program manager, I have a leadership role in several grants, research and research development, program management, and publication. I’ve led and co-authored many publications in the field of genomic medicine and molecular diagnostics.

    My research focuses on new technologies and equitable implementation in healthcare, focusing on precision medicine, cardiovascular disease, cancer, and diverse populations. My research spans a variety of disciplines, including clinical and social sciences, in the academic, government, and industry sectors. I have extensive expertise in genomic laboratory medicine, evidence-based reviews of molecular-based testing, personalized medicine, and research program management.

    I have been working with researchers in the precision medicine field for over 23 years in varying organizations, including the Centers for Disease Control and Prevention’s Office of Genomics and Precision Public Health, Blue Cross Blue Shield Association’s Technical Evaluation Center, and Bayer Diagnostics.

    Collapse Research 
    Collapse Research Activities and Funding
    BUILDING THE EVIDENCE BASE FOR APPROPRIATE AND EFFICIENT IMPLEMENTATION OF EMERGING GENOMIC TESTS FOR DISEASE MANAGEMENT AND SCREENING
    NIH R01HG011792Jul 8, 2021 - Apr 30, 2026
    Role: Co-Investigator
    California Initiative to Advance Precision Medicine Sep 1, 2019 - Aug 31, 2022
    Role: Collaborator
    Prevention of Fractures in Patients with Parkinson's Disease
    NIH R01AG059417Sep 30, 2018 - May 31, 2023
    Role: Co-Investigator
    Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions
    NIH R01CA221870Jul 1, 2018 - Jun 30, 2021
    Role: Co-Investigator
    Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions
    NIH R01CA221870Jul 1, 2018 - Jun 30, 2021
    Role: Co-Investigator
    Genomic sequencing to aid diagnosis in pediatric and prenatal practice: Examining clinical utility, ethical implications, payer coverage, and data integration in a diverse population.
    NIH U01HG009599Aug 4, 2017 - May 31, 2022
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis. Mol Diagn Ther. 2024 Aug 02. Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP. PMID: 39093546.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. SLCO1B1 functional variants and statin-induced myopathy in people with recent genealogical ancestors from Africa: a population-based real-world study. medRxiv. 2023 Dec 03. Yee SW, Haldar T, Kvale M, Yang J, Douglas MP, Oni-Orisan A. PMID: 38076949; PMCID: PMC10705643.
      View in: PubMed   Mentions:
    3. Clinical validity and utility of circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): a systematic literature review and meta-analysis. medRxiv. 2023 Oct 28. Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP. PMID: 37961510; PMCID: PMC10635208.
      View in: PubMed   Mentions:
    4. The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis. Value Health. 2023 12; 26(12):1697-1710. Jansen JP, Ragavan MV, Chen C, Douglas MP, Phillips KA. PMID: 37741446; PMCID: PMC10859998.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy. Health Aff Sch. 2023 Jul; 1(1):qxad005. Trosman JR, Weldon CB, Kurian AW, Pasquinelli MM, Kircher SM, Martin N, Douglas MP, Phillips KA. PMID: 38756840; PMCID: PMC10986216.
      View in: PubMed   Mentions: 3  
    6. Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment. J Natl Compr Canc Netw. 2023 06; 21(6):609-616.e4. Douglas MP, Ragavan MV, Chen C, Kumar A, Gray SW, Blakely CM, Phillips KA. PMID: 37308126; PMCID: PMC10846388.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    7. Transmission of SARS-CoV-2 Delta variant from an infected aircrew member on a short-haul domestic flight, Australia 2021. J Travel Med. 2022 12 27; 29(8). Williamson KM, Butler M, Elton B, Taylor J, Islam F, Douglas MP, Kirk MD, Durrheim DN. PMID: 36448584; PMCID: PMC9793396.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    8. Genetic counselors' experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes. J Genet Couns. 2022 12; 31(6):1394-1403. Weldon CB, Trosman JR, Liang SY, Douglas MP, Scheuner MT, Kurian A, Schaa KL, Roscow B, Erwin D, Phillips KA. PMID: 35900261; PMCID: PMC9722528.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Analyzing Precision Medicine Utilization with Real-World Data: A Scoping Review. J Pers Med. 2022 Apr 01; 12(4). Douglas MP, Kumar A. PMID: 35455673; PMCID: PMC9025578.
      View in: PubMed   Mentions: 3  
    10. Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access. Health Aff (Millwood). 2022 03; 41(3):383-389. Deverka PA, Douglas MP, Phillips KA. PMID: 35254936; PMCID: PMC8962120.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    11. Geriatricians' Perspectives on the Multiple Dimensions of Utility of Genetic Testing for Alzheimer's Disease: A Qualitative Study. J Alzheimers Dis. 2022; 90(3):1011-1019. Arias JJ, Lin GA, Tyler AM, Douglas MP, Phillips KA. PMID: 35871355; PMCID: PMC9712158.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER). Genet Med. 2022 01; 24(1):238-244. Phillips KA, Trosman JR, Douglas MP, Gelb BD, Ferket BS, Hindorff LA, Slavotinek AM, Berg JS, Russell HV, Devine B, Greve V, Smith HS. PMID: 34906461; PMCID: PMC8962136.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    13. Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants. J Community Genet. 2022 Feb; 13(1):75-80. Douglas MP, Lin GA, Trosman JR, Phillips KA. PMID: 34743282; PMCID: PMC8799811.
      View in: PubMed   Mentions: 2  
    14. Multicancer hereditary syndrome testing: Genetic counselors’ perspectives. Journal of Clinical Oncology. 2021 Oct 1; 39(28_suppl):106-106. Weldon WC, Liang LS, Phillips PK, Douglas DM, Scheuner SM, Kurian KA, Schaa SK, Roscow RB, Erwin ED, Trosman TJ. .
      View in: Publisher Site   Mentions:
    15. Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. J Genet Couns. 2022 02; 31(1):130-139. Lin GA, Trosman JR, Douglas MP, Weldon CB, Scheuner MT, Kurian A, Phillips KA. PMID: 34231930; PMCID: PMC8893352.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    16. Multicancer hereditary syndrome testing: Genetic counselors’ perspectives. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):10594-10594. Weldon WC, Liang LS, Phillips PK, Douglas DM, Scheuner SM, Kurian KA, Schaa SK, Roscow RB, Erwin ED, Trosman TJ. .
      View in: Publisher Site   Mentions:
    17. Laboratory business models and practices: implications for availability and access to germline genetic testing. Genet Med. 2021 09; 23(9):1681-1688. Scheuner MT, Douglas MP, Sales P, Ackerman SL, Phillips KA. PMID: 33958748; PMCID: PMC8460432.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    18. OP511 Financing of germline testing: implications for availability and access. Molecular Genetics and Metabolism. 2021 Apr 1; 132:s330-s331. Lin LG, Scheuner SM, Trosman TJ, Sales SP, Ackerman AS, Douglas DM, Weldon WC, Kurian KA, Phillips PK. .
      View in: Publisher Site   Mentions:
    19. Availability and funding of clinical genomic sequencing globally. BMJ Glob Health. 2021 02; 6(2). Phillips KA, Douglas MP, Wordsworth S, Buchanan J, Marshall DA. PMID: 33574068; PMCID: PMC7880109.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    20. Private payer coverage policies for ApoE-e4 genetic testing. Genet Med. 2021 04; 23(4):614-620. Arias JJ, Tyler AM, Douglas MP, Phillips KA. PMID: 33420342; PMCID: PMC8035237.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    21. Expanding Use of Clinical Genome Sequencing and the Need for More Data on Implementation. JAMA. 2020 11 24; 324(20):2029-2030. Phillips KA, Douglas MP, Marshall DA. PMID: 33104159; PMCID: PMC7686292.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    22. PCV3 Global Landscape of Clinical Genomic Sequencing: Who, Where, and How?. Value in Health Regional Issues. 2020 Sep 1; 22:s26. Phillips PK, Wordsworth WS, Regier RD, Marshall MD, Douglas DM, Buchanan BJ. .
      View in: Publisher Site   Mentions:
    23. Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019. J Natl Compr Canc Netw. 2020 07; 18(7):866-872. Douglas MP, Gray SW, Phillips KA. PMID: 32634780; PMCID: PMC7347155.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    24. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions. Value Health. 2020 05; 23(5):540-550. Deverka PA, Douglas MP, Phillips KA. PMID: 32389218; PMCID: PMC7219085.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    25. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. Value Health. 2020 05; 23(5):551-558. Trosman JR, Douglas MP, Liang SY, Weldon CB, Kurian AW, Kelley RK, Phillips KA. PMID: 32389219; PMCID: PMC7217867.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    26. Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). Genet Med. 2020 02; 22(2):283-291. Trosman JR, Weldon CB, Slavotinek A, Norton ME, Douglas MP, Phillips KA. PMID: 31501586; PMCID: PMC7004856.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    27. Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs. JAMA. 2019 06 25; 321(24):2403-2404. Phillips KA, Trosman JR, Douglas MP. PMID: 31145414; PMCID: PMC6684382.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    28. New Medicare Coverage Policy for Next-Generation Tumor Sequencing: A Key Shift in Coverage Criteria With Broad Implications Beyond Medicare. JCO Precis Oncol. 2018; 2. Phillips KA, Trosman JR, Weldon CB, Douglas MP. PMID: 31073549; PMCID: PMC6503521.
      View in: PubMed   Mentions: 5     Fields:    
    29. The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace. J Precis Med. 2018 Oct; 4. Phillips KA, Douglas MP. PMID: 32149190; PMCID: PMC7059995.
      View in: PubMed   Mentions: 9  
    30. Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited. Genet Med. 2019 01; 21(1):152-160. Douglas MP, Parker SL, Trosman JR, Slavotinek AM, Phillips KA. PMID: 29997388; PMCID: PMC6329652.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    31. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? Health Aff (Millwood). 2018 05; 37(5):710-716. Phillips KA, Deverka PA, Hooker GW, Douglas MP. PMID: 29733704; PMCID: PMC5987210.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    32. Insurance coverage for genomic tests. Science. 2018 Apr 20; 360(6386):278-279. Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP, Douglas MP, Weldon CB. PMID: 29674586; PMCID: PMC5991085.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    33. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018 12; 20(12):1544-1553. Christensen KD, Vassy JL, Phillips KA, Blout CL, Azzariti DR, Lu CY, Robinson JO, Lee K, Douglas MP, Yeh JM, Machini K, Stout NK, Rehm HL, McGuire AL, Green RC, Dukhovny D, MedSeq Project. PMID: 29565423; PMCID: PMC6151171.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    34. Corrigendum: What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2018 01; 20(1):165. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. PMID: 29261179.
      View in: PubMed   Mentions:    Fields:    
    35. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS. Int J Technol Assess Health Care. 2017 Jan; 33(4):534-540. Chambers JD, Saret CJ, Anderson JE, Deverka PA, Douglas MP, Phillips KA. PMID: 29065945; PMCID: PMC5732073.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    36. Payer coverage policies for multigene tests. Nat Biotechnol. 2017 07 12; 35(7):614-617. Phillips KA, Deverka PA, Trosman JR, Douglas MP, Chambers JD, Weldon CB, Dervan AP. PMID: 28700544; PMCID: PMC5553867.
      View in: PubMed   Mentions: 22     Fields:    
    37. The price of whole-genome sequencing may be decreasing, but who will be sequenced? Per Med. 2017 May; 14(3):203-211. Marshall DA, MacDonald KV, Robinson JO, Barcellos LF, Gianfrancesco M, Helm M, McGuire A, Green RC, Douglas MP, Goldman MA, Phillips KA. PMID: 28993792; PMCID: PMC5629976.
      View in: PubMed   Mentions: 5     Fields:    
    38. Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med. 2017 10; 19(10):1081-1091. Phillips KA, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas MP. PMID: 28406488; PMCID: PMC5629101.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    39. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017 02; 15(2):219-228. Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. PMID: 28188191; PMCID: PMC5508568.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    40. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Value Health. 2017 01; 20(1):47-53. Phillips KA, Douglas MP, Trosman JR, Marshall DA. PMID: 28212968; PMCID: PMC5319740.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    41. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value Health. 2017 01; 20(1):40-46. Trosman JR, Weldon CB, Douglas MP, Deverka PA, Watkins JB, Phillips KA. PMID: 28212967; PMCID: PMC5319741.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    42. Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. Genet Med. 2017 05; 19(5):559-567. Dervan AP, Deverka PA, Trosman JR, Weldon CB, Douglas MP, Phillips KA. PMID: 27657682; PMCID: PMC5362360.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    43. What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2016 12; 18(12):1295-1302. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. PMID: 27253734; PMCID: PMC5133139.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    44. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol. 2015 Sep; 33(9):900-2. Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips KA. PMID: 26348951; PMCID: PMC4625918.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    45. Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genet Med. 2016 Feb; 18(2):111-6. Douglas MP, Ladabaum U, Pletcher MJ, Marshall DA, Phillips KA. PMID: 25996638; PMCID: PMC4654986.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    46. Addressing lack of US insurance coverage of Cancer Hereditary Multiplex Testing (CHMT). Journal of Clinical Oncology. 2015 May 20; 33(15_suppl):e17515-e17515. Trosman TJ, Weldon WC, Kurian KA, Douglas DM, Kelley KR, Phillips PK. .
      View in: Publisher Site   Mentions:
    47. PND45 What are people willing to pay for whole genome sequencing information?. Value in Health. 2015 May 1; 18(3):a285-a286. Marshall MD, Gonzalez GJ, Johnson JF, Pugh PA, MacDonald MK, Douglas DM, Phillips PK. .
      View in: Publisher Site   Mentions:
    48. Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Genet Med. 2015 Apr; 17(4):314-5. Phillips KA, Ladabaum U, Pletcher MJ, Marshall DA, Douglas MP. PMID: 25835195; PMCID: PMC4395812.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    49. Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology. Per Med. 2015 Jan 01; 12(1):13-22. Garfeld S, Douglas MP, MacDonald KV, Marshall DA, Phillips KA. PMID: 25620993; PMCID: PMC4303575.
      View in: PubMed   Mentions: 6     Fields:    
    50. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood). 2014 Jul; 33(7):1246-53. Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB. PMID: 25006153; PMCID: PMC4113721.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    51. Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clin Pharmacol Ther. 2014 Apr; 95(4):394-402. Dotson WD, Douglas MP, Kolor K, Stewart AC, Bowen MS, Gwinn M, Wulf A, Anders HM, Chang CQ, Clyne M, Lam TK, Schully SD, Marrone M, Feero WG, Khoury MJ. PMID: 24398597; PMCID: PMC4689130.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    52. Horizon scanning for translational genomic research beyond bench to bedside. Genet Med. 2014 Jul; 16(7):535-8. Clyne M, Schully SD, Dotson WD, Douglas MP, Gwinn M, Kolor K, Wulf A, Bowen MS, Khoury MJ. PMID: 24406461; PMCID: PMC4079725.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    53. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2014 Mar; 16(3):251-7. Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang SY, Neumann P. PMID: 24232413; PMCID: PMC3949119.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    54. Use of genomic panels to determine risk of developing type 2 diabetes in the general population: a targeted evidence-based review. Genet Med. 2013 Aug; 15(8):600-11. Palomaki GE, Melillo S, Marrone M, Douglas MP. PMID: 23492876; PMCID: PMC4684162.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    55. Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategies--a targeted evidence-based review. Genet Med. 2010 Dec; 12(12):772-84. Palomaki GE, Melillo S, Neveux L, Douglas MP, Dotson WD, Janssens AC, Balkite EA, Bradley LA. PMID: 21045709.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    56. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009 Jan; 11(1):3-14. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO, EGAPP Working Group. PMID: 18813139; PMCID: PMC2743609.
      View in: PubMed   Mentions: 264     Fields:    Translation:Humans
    57. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med. 2009 Jan; 11(1):21-34. Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD. PMID: 19125129; PMCID: PMC2743611.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    58. Taxonomic variation in the Mycobacterium fortuitum third biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates. Int J Syst Evol Microbiol. 2004 Sep; 54(Pt 5):1653-1667. Schinsky MF, Morey RE, Steigerwalt AG, Douglas MP, Wilson RW, Floyd MM, Butler WR, Daneshvar MI, Brown-Elliott BA, Wallace RJ, McNeil MM, Brenner DJ, Brown JM. PMID: 15388725.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    59. Paracoccus yeeii sp. nov. (formerly CDC group EO-2), a novel bacterial species associated with human infection. J Clin Microbiol. 2003 Mar; 41(3):1289-94. Daneshvar MI, Hollis DG, Weyant RS, Steigerwalt AG, Whitney AM, Douglas MP, Macgregor JP, Jordan JG, Mayer LW, Rassouli SM, Barchet W, Munro C, Shuttleworth L, Bernard K. PMID: 12624070; PMCID: PMC150304.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    60. Cellular fatty acid composition of Lautropia mirabilis. J Clin Microbiol. 2001 Nov; 39(11):4160-2. Daneshvar MI, Douglas MP, Weyant RS. PMID: 11682548; PMCID: PMC88505.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    61. Enterococcus porcinus sp. nov. and Enterococcus ratti sp. nov., associated with enteric disorders in animals. Int J Syst Evol Microbiol. 2001 Sep; 51(Pt 5):1737-1743. Teixeira LM, Carvalho MG, Espinola MM, Steigerwalt AG, Douglas MP, Brenner DJ, Facklam RR. PMID: 11594604.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    62. Assignment of CDC weak oxidizer group 2 (WO-2) to the genus Pandoraea and characterization of three new Pandoraea genomospecies. J Clin Microbiol. 2001 May; 39(5):1819-26. Daneshvar MI, Hollis DG, Steigerwalt AG, Whitney AM, Spangler L, Douglas MP, Jordan JG, MacGregor JP, Hill BC, Tenover FC, Brenner DJ, Weyant RS. PMID: 11325997; PMCID: PMC88032.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    63. DNA damage caused by common cytological fixatives. Mutat Res. 1998 Jun 05; 401(1-2):77-88. Douglas MP, Rogers SO. PMID: 9639679.
      View in: PubMed   Mentions: 35     Fields:    Translation:Animals
    Michael's Networks
    Concepts (180)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (14)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-5-g94c7c43e on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.